Overview

A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Treatments:
Carboplatin
Cisplatin
Crizotinib
Pemetrexed